Published on 30 Jan 2023 on Insider Monkey via Yahoo Finance
Here’s Why Eli Lilly and Company (LLY) Rose in Q4
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P 500 Index. The fund fell 16.90% in 2022, compared to a 6.10% decline for the Russell 3000 Health Care Index and an 18.11% decline for the S&P 500 Index. Factors like cash exposure in the up-market, adverse stock selection, and differences in sub-industry exposures led the fund to underperform in the quarter relative to its benchmark. In addition, please check the fund’s top five holdings to know its best picks in 2022.
Baron Funds highlighted stocks like Eli Lilly and Company (NYSE:LLY) in the Q4 2022 investor letter. Headquartered in Indianapolis, Indiana, Eli Lilly and Company (NYSE:LLY) is a pharmaceuticals company. On January 27, 2023, Eli Lilly and Company (NYSE:LLY) stock closed at $342.10 per share. One-month return of Eli Lilly and Company (NYSE:LLY) was -6.49%, and its shares gained 39.41% of their value over the last 52 weeks. Eli Lilly and Company (NYSE:LLY) has a market capitalization of $325.056 billion.
Baron Funds made the following comment about Eli Lilly and Company (NYSE:LLY) in its Q4 2022 investor letter: